CollPlant Biotechnologies Ltd. (CLGN)

5.24 +0.10 (+1.95%) At close: 04:00PM EDT

CollPlant Biotechnologies Ltd.

Weizmann Science Park
4 Oppenheimer
Rehovot 7670104
Israel
972 73 232 5600
https://www.collplant.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 75

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Yehiel Tal	CEO & Director	751k	N/A	1952
Mr. Oren Fahimipoor	Vice President of Operations	212k	N/A	1982
Dr. Elana Gazal	Vice President of Research & Development	379k	N/A	1975
Prof. Oded Shoseyov	Founder & Chief Scientist	384k	N/A	1956
Ms. Hadas Dreiher Horowitz	Vice President of Human Resources	N/A	N/A	1977

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Corporate governance

CollPlant Biotechnologies Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.